MyGevity Unifies DNA, Biological Age, and Lab Data on One Platform

ST. PETERSBURG, FL – April 02, 2026 – Health technology company MyGevity today announced the nationwide launch of an integrated platform designed to untangle the increasingly complex web of personal health data. The new system consolidates at-home genetic testing, epigenetic biological age assessment, and clinical lab diagnostics into a single, cohesive dashboard, aiming to give users a clearer, more holistic view of their health.

The launch marks the culmination of a multi-year effort to address a common frustration for health-conscious consumers: managing disparate, often confusing reports from multiple testing services. The platform was born from the personal experience of CEO Will Barton, who founded the company after struggling to manage his own health test results.

“Most systems give data in different formats and with varying levels of explanation,” Barton said in a statement. “Our goal with MyGevity was to create a structured, centralized platform that presents this information more cohesively.”

A Unified Dashboard for Fragmented Health

MyGevity's core offering is its integration of three key pillars of health data. The platform connects at-home DNA tests processed in CLIA-certified labs, biological age testing that uses the scientifically validated DunedinPACE algorithm, and comprehensive blood biomarker panels conducted through a partnership with Quest Diagnostics.

Instead of delivering separate reports, the system aggregates these results into a unified digital dashboard. The company employs an internal AI-supported framework to analyze data points across these categories, aiming to highlight patterns and areas of potential relevance for the user. However, company officials are quick to clarify the system's role.

“The objective is to help people view their information in a way that is easier to navigate,” noted Chief Medical Officer Dr. Allen Meglin. He emphasized that the platform is designed for organization, not prediction or diagnosis. “Many individuals receive complex laboratory and genomic data that can be difficult to interpret on their own. The platform is intended to connect these data sources so users can view them side by side.” This focus on clarity over clinical interpretation positions MyGevity as an organizational tool in the burgeoning field of personal health analytics.

Navigating a Crowded and Cautious Market

MyGevity enters a competitive landscape populated by established players like 23andMe, known for its FDA-authorized health reports, and InsideTracker, which provides personalized nutrition and lifestyle recommendations based on biomarker analysis. To stand out, the Florida-based firm is banking on its unique combination of services and business model.

The inclusion of the DunedinPACE algorithm is a key differentiator. Developed through long-term research at Duke and Columbia Universities, this epigenetic clock measures the pace of aging rather than just assigning a biological age number, a metric considered by researchers to be more responsive to lifestyle interventions. This contrasts with other biological age tests on the market and appeals to those focused on longevity.

Furthermore, the company's strategic partnership with Quest Diagnostics provides immediate credibility and nationwide logistical support, allowing users to complete bloodwork at more than 2,000 patient service centers. This collaboration allows MyGevity to focus on its technology platform while leveraging the infrastructure of a diagnostics industry leader.

Perhaps most distinctively, MyGevity is launching without a mandatory subscription model. Competitors often gate their premium features or ongoing insights behind annual memberships. MyGevity allows users to purchase test kits and lab panels à la carte, a move that could attract consumers wary of recurring fees.

The Promise and Peril of Personal Data

As consumers upload their most sensitive biological information to digital platforms, questions of data privacy and security have become paramount. The industry has been shaken by incidents like the 2023 23andMe data breach, which compromised the information of millions of users and underscored the significant risks associated with centralized genetic databases.

MyGevity states that all user data is encrypted, managed in accordance with HIPAA requirements, and will not be sold. While such claims are standard, the regulatory landscape for direct-to-consumer (DTC) health companies is complex. HIPAA typically applies to “covered entities” like hospitals and health insurers, and many DTC firms fall outside this definition. However, MyGevity's partnerships with CLIA-certified labs and Quest Diagnostics likely involve Business Associate Agreements that bring aspects of their data handling under the HIPAA framework.

Scrutiny of the company’s privacy policy reveals that while it does not sell identifiable data, it may create and share aggregated, de-identified data with third parties for research and business purposes—a common practice in the industry. For consumers, the decision to use such a platform requires a significant level of trust, balancing the promise of personalized insight against the inherent risks of sharing immutable genetic information.

From Data Points to Direction

Beyond its AI-powered dashboard, MyGevity is adding a human touch to help users make sense of their results. Every DNA kit purchase includes access to a session with a personal genomics coach. These coaches are tasked with helping users navigate the platform and understand the structure of their reports, translating complex scientific information into a more digestible format.

This coaching component is designed to bridge the critical gap between data and actionable understanding. While the platform itself avoids making medical recommendations, the coaches can provide context and guidance on how to interpret the information within a wellness framework. The company stresses that this guidance is informational and is not a substitute for clinical medical advice from a qualified healthcare provider.

The user journey is designed for convenience. DNA and biological age kits are mailed to a user's home, while lab work is completed with a simple visit to a local Quest Diagnostics facility. Once all results are processed, they populate the user's secure online portal, presenting a multi-faceted snapshot of their current health.

By combining advanced algorithms, validated biometrics, and human guidance, MyGevity aims to transform a flood of isolated data points into a source of clear, personal direction for individuals navigating their own health and wellness journeys.